{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T23:10:16Z","timestamp":1702163416419},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T00:00:00Z","timestamp":1680134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T00:00:00Z","timestamp":1680134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s00115-023-01462-y","type":"journal-article","created":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T14:07:34Z","timestamp":1680185254000},"page":"488-493","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Update zur medikament\u00f6sen Behandlung der spinalen Muskelatrophie","Update on drug treatment of spinal muscular atrophy"],"prefix":"10.1007","volume":"94","author":[{"given":"Heike","family":"K\u00f6lbel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Hagenacker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,30]]},"reference":[{"issue":"4","key":"1462_CR1","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.tins.2020.11.009","volume":"44","author":"B Wirth","year":"2021","unstructured":"Wirth\u00a0B (2021) Spinal muscular atrophy: in the challenge lies a\u00a0solution. Trends Neurosci 44(4):306\u2013322","journal-title":"Trends Neurosci"},{"key":"1462_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2018.4","author":"EJN Groen","year":"2018","unstructured":"Groen\u00a0EJN, Talbot\u00a0K, Gillingwater\u00a0TH (2018) Advances in therapy for spinal muscular atrophy: promises and challenges. Nat Rev Neurol. https:\/\/doi.org\/10.1038\/nrneurol.2018.4","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"1462_CR3","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13023-021-01783-8","volume":"16","author":"K Vill","year":"2021","unstructured":"Vill\u00a0K, Schwartz\u00a0O, Blaschek\u00a0A, Gl\u00e4ser\u00a0D, Nennstiel\u00a0U, Wirth\u00a0B, Burggraf\u00a0S, R\u00f6schinger\u00a0W, Becker\u00a0M, Czibere\u00a0L et\u00a0al (2021) Newborn screening for spinal muscular atrophy in Germany: clinical results after 2\u00a0years. Orphanet J Rare Dis 16(1):153","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"1462_CR4","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3233\/JND-221577","volume":"10","author":"W M\u00fcller-Felber","year":"2023","unstructured":"M\u00fcller-Felber\u00a0W, Blaschek\u00a0A, Schwartz\u00a0O, Gl\u00e4ser\u00a0D, Nennstiel\u00a0U, Brockow\u00a0I, Wirth\u00a0B, Burggraf\u00a0S, R\u00f6schinger\u00a0W, Becker\u00a0M et al (2023) Newbornscreening SMA - from pilot project to nationwide screening in Germany. J\u00a0Neuromuscul Dis 10(1):55\u201365","journal-title":"J Neuromuscul Dis"},{"issue":"6","key":"1462_CR5","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1007\/s00115-020-00919-8","volume":"91","author":"A Ziegler","year":"2020","unstructured":"Ziegler\u00a0A, Wilichowski\u00a0E, Schara\u00a0U, Hahn\u00a0A, M\u00fcller-Felber\u00a0W, Johannsen\u00a0J, von Moers\u00a0A, von der von Hagen\u00a0M, Stoltenburg\u00a0C, Saffari\u00a0A et al (2020) Recommendations for gene therapy of spinal muscular atrophy with onasemnogene abeparvovec-AVXS-101 : Consensus paper of the German representatives of the Society for Pediatric Neurology (GNP) and the German treatment centers with collaboration of the medical scientific advisory board of the German Society for Muscular Diseases (DGM). Nervenarzt 91(6):518\u2013529","journal-title":"Nervenarzt"},{"issue":"1","key":"1462_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2352-4642(21)00287-X","volume":"6","author":"C Wei\u00df","year":"2022","unstructured":"Wei\u00df\u00a0C, Ziegler\u00a0A, Becker\u00a0LL, Johannsen\u00a0J, Brennenstuhl\u00a0H, Schreiber\u00a0G, Flotats-Bastardas\u00a0M, Stoltenburg\u00a0C, Hartmann\u00a0H, Illsinger\u00a0S et al (2022) Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24\u00a0months or younger and bodyweight up to 15\u202fkg: an observational cohort study. Lancet Child Adolesc Health 6(1):17\u201327","journal-title":"Lancet Child Adolesc Health"},{"issue":"7","key":"1462_CR7","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","volume":"28","author":"KA Strauss","year":"2022","unstructured":"Strauss\u00a0KA, Farrar\u00a0MA, Muntoni\u00a0F, Saito\u00a0K, Mendell\u00a0JR, Servais\u00a0L, McMillan\u00a0HJ, Finkel\u00a0RS, Swoboda\u00a0KJ, Kwon\u00a0JM et\u00a0al (2022) Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial. Nat Med 28(7):1381\u20131389","journal-title":"Nat Med"},{"issue":"7","key":"1462_CR8","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","volume":"28","author":"KA Strauss","year":"2022","unstructured":"Strauss\u00a0KA, Farrar\u00a0MA, Muntoni\u00a0F, Saito\u00a0K, Mendell\u00a0JR, Servais\u00a0L, McMillan\u00a0HJ, Finkel\u00a0RS, Swoboda\u00a0KJ, Kwon\u00a0JM et\u00a0al (2022) Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial. Nat Med 28(7):1390\u20131397","journal-title":"Nat Med"},{"issue":"10","key":"1462_CR9","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1080\/14737175.2017.1364159","volume":"17","author":"CA Chiriboga","year":"2017","unstructured":"Chiriboga\u00a0CA (2017) Nusinersen for the treatment of spinal muscular atrophy. Expert Rev Neurother 17(10):955\u2013962","journal-title":"Expert Rev Neurother"},{"issue":"18","key":"1462_CR10","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel\u00a0RS, Mercuri\u00a0E, Darras\u00a0BT, Connolly\u00a0AM, Kuntz\u00a0NL, Kirschner\u00a0J, Chiriboga\u00a0CA, Saito\u00a0K, Servais\u00a0L, Tizzano\u00a0E et al (2017) Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N\u00a0Engl J Med 377(18):1723\u20131732","journal-title":"N Engl J Med"},{"issue":"11","key":"1462_CR11","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","volume":"29","author":"DC De Vivo","year":"2019","unstructured":"De Vivo\u00a0DC, Bertini\u00a0E, Swoboda\u00a0KJ, Hwu\u00a0WL, Crawford\u00a0TO, Finkel\u00a0RS, Kirschner\u00a0J, Kuntz\u00a0NL, Parsons\u00a0JA, Ryan\u00a0MM et\u00a0al (2019) Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscul Disord 29(11):842\u2013856","journal-title":"Neuromuscul Disord"},{"issue":"7","key":"1462_CR12","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","volume":"378","author":"E Mercuri","year":"2018","unstructured":"Mercuri\u00a0E, Darras\u00a0BT, Chiriboga\u00a0CA, Day\u00a0JW, Campbell\u00a0C, Connolly\u00a0AM, Iannaccone\u00a0ST, Kirschner\u00a0J, Kuntz\u00a0NL, Saito\u00a0K et al (2018) Nusinersen versus sham control in later-onset spinal muscular atrophy. N\u00a0Engl J Med 378(7):625\u2013635","journal-title":"N Engl J Med"},{"issue":"1","key":"1462_CR13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3233\/JND-221600","volume":"10","author":"A Pechmann","year":"2022","unstructured":"Pechmann\u00a0A, Behrens\u00a0M, D\u00f6rnbrack\u00a0K, Tassoni\u00a0A, Wenzel\u00a0F, Stein\u00a0S, Vogt\u00a0S, Z\u00f6ller\u00a0D, Bernert\u00a0G, Hagenacker\u00a0T et al (2022) Improvements in walking distance during nusinersen treatment\u00a0\u2013 a\u00a0prospective 3\u2011year SMArtCARE registry study. J\u00a0Neuromuscul Dis 10(1):29\u201340. https:\/\/doi.org\/10.3233\/JND-221600","journal-title":"J\u00a0Neuromuscul Dis"},{"issue":"1","key":"1462_CR14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3233\/JND-190441","volume":"7","author":"A Pechmann","year":"2020","unstructured":"Pechmann\u00a0A, Baumann\u00a0M, Bernert\u00a0G, Flotats-Bastardas\u00a0M, Gruber-Sedlmayr\u00a0U, von der Hagen\u00a0M, Hasselmann\u00a0O, Hobbiebrunken\u00a0E, Horber\u00a0V, Johannsen\u00a0J et al (2020) Treatment with nusinersen - challenges regarding the indication for children with SMA type 1. J\u00a0Neuromuscul Dis 7(1):41\u201346","journal-title":"J Neuromuscul Dis"},{"issue":"1","key":"1462_CR15","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1186\/s13023-022-02547-8","volume":"17","author":"A Pechmann","year":"2022","unstructured":"Pechmann\u00a0A, Behrens\u00a0M, D\u00f6rnbrack\u00a0K, Tassoni\u00a0A, Wenzel\u00a0F, Stein\u00a0S, Vogt\u00a0S, Z\u00f6ller\u00a0D, Bernert\u00a0G, Hagenacker\u00a0T et al (2022) Improved upper limb function in non-ambulant children with SMA type 2 and 3 during nusinersen treatment: a\u00a0prospective 3\u2011years SMArtCARE registry study. Orphanet J Rare Dis 17(1):384","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"1462_CR16","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1055\/s-0040-1718916","volume":"52","author":"J Johannsen","year":"2021","unstructured":"Johannsen\u00a0J, Weiss\u00a0D, Schlenker\u00a0F, Groth\u00a0M, Denecke\u00a0J (2021) Intrathecal administration of nusinersen in pediatric SMA patients with and without spine deformities: experiences and challenges over 3 years in a\u00a0single center. Neuropediatrics 52(3):179\u2013185","journal-title":"Neuropediatrics"},{"issue":"5","key":"1462_CR17","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1080\/13543784.2022.2056836","volume":"31","author":"T Markati","year":"2022","unstructured":"Markati\u00a0T, Fisher\u00a0G, Ramdas\u00a0S, Servais\u00a0L (2022) Risdiplam: an investigational survival motor neuron 2 (SMN2) splicing modifier for spinal muscular atrophy (SMA). Expert Opin Investig Drugs 31(5):451\u2013461","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"1462_CR18","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S1474-4422(21)00367-7","volume":"21","author":"E Mercuri","year":"2022","unstructured":"Mercuri\u00a0E, Deconinck\u00a0N, Mazzone\u00a0ES, Nascimento\u00a0A, Oskoui\u00a0M, Saito\u00a0K, Vuillerot\u00a0C, Baranello\u00a0G, Boespflug-Tanguy\u00a0O, Goemans\u00a0N et al (2022) Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a\u00a0phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurol 21(1):42\u201352","journal-title":"Lancet Neurol"},{"issue":"12","key":"1462_CR19","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/S1474-4422(22)00339-8","volume":"21","author":"R Masson","year":"2022","unstructured":"Masson\u00a0R, Mazurkiewicz-Be\u0142dzi\u0144ska\u00a0M, Rose\u00a0K, Servais\u00a0L, Xiong\u00a0H, Zanoteli\u00a0E, Baranello\u00a0G, Bruno\u00a0C, Day\u00a0JW, Deconinck\u00a0N et al (2022) Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial. Lancet Neurol 21(12):1110\u20131119","journal-title":"Lancet Neurol"},{"issue":"15 Supplement","key":"1462_CR20","doi-asserted-by":"crossref","first-page":"4281","DOI":"10.1212\/WNL.96.15_supplement.4281","volume":"96","author":"RS Finkel","year":"2021","unstructured":"Finkel\u00a0RS, Al-Muhaizea\u00a0M, Farrar\u00a0MA, Nelson\u00a0L, Prufer\u00a0A, Servais\u00a0L, Wang\u00a0Y, Zanoteli\u00a0E, Palfreeman\u00a0L, El-Khairi\u00a0M et al (2021) RAINBOWFISH: a study of risdiplam in newborns with presymptomatic spinal muscular atrophy (SMA) (4281). Neurology 96(15 Supplement):4281","journal-title":"Neurology"},{"issue":"3","key":"1462_CR21","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/ene.13534","volume":"25","author":"RI Wadman","year":"2018","unstructured":"Wadman\u00a0RI, Wijngaarde\u00a0CA, Stam\u00a0M, Bartels\u00a0B, Otto\u00a0LAM, Lemmink\u00a0HH, Schoenmakers\u00a0M, Cuppen\u00a0I, van den Berg\u00a0LH, van der Pol\u00a0WL (2018) Muscle strength and motor function throughout life in a\u00a0cross-sectional cohort of 180\u00a0patients with spinal muscular atrophy types 1c\u20114. Eur J Neurol 25(3):512\u2013518","journal-title":"Eur J Neurol"},{"issue":"6","key":"1462_CR22","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1001\/archneurol.2010.373","volume":"68","author":"P Kaufmann","year":"2011","unstructured":"Kaufmann\u00a0P, McDermott\u00a0MP, Darras\u00a0BT, Finkel\u00a0R, Kang\u00a0P, Oskoui\u00a0M, Constantinescu\u00a0A, Sproule\u00a0DM, Foley\u00a0AR, Yang\u00a0M et\u00a0al (2011) Observational study of spinal muscular atrophy type 2 and 3: functional outcomes over 1\u00a0year. Arch Neurol 68(6):779\u2013786","journal-title":"Arch Neurol"},{"issue":"4","key":"1462_CR23","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3233\/JND-190416","volume":"6","author":"MC Walter","year":"2019","unstructured":"Walter\u00a0MC, Wenninger\u00a0S, Thiele\u00a0S, Stauber\u00a0J, Hiebeler\u00a0M, Greckl\u00a0E, Stahl\u00a0K, Pechmann\u00a0A, Lochm\u00fcller\u00a0H, Kirschner\u00a0J et al (2019) Safety and treatment effects of nusinersen in longstanding adult 5q-SMA type 3 - a prospective observational study. J\u00a0Neuromuscul Dis 6(4):453\u2013465","journal-title":"J Neuromuscul Dis"},{"issue":"4","key":"1462_CR24","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S1474-4422(20)30037-5","volume":"19","author":"T Hagenacker","year":"2020","unstructured":"Hagenacker\u00a0T, Wurster\u00a0CD, G\u00fcnther\u00a0R, Schreiber-Katz\u00a0O, Osmanovic\u00a0A, Petri\u00a0S, Weiler\u00a0M, Ziegler\u00a0A, Kuttler\u00a0J, Koch\u00a0JC et al (2020) Nusinersen in adults with 5q spinal muscular atrophy: a\u00a0non-interventional, multicentre, observational cohort study. Lancet Neurol 19(4):317\u2013325","journal-title":"Lancet Neurol"},{"issue":"1","key":"1462_CR25","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1186\/s13023-021-02065-z","volume":"16","author":"G Coratti","year":"2021","unstructured":"Coratti\u00a0G, Cutrona\u00a0C, Pera\u00a0MC, Bovis\u00a0F, Ponzano\u00a0M, Chieppa\u00a0F, Antonaci\u00a0L, Sansone\u00a0V, Finkel\u00a0R, Pane\u00a0M et al (2021) Motor function in type 2 and 3 SMA patients treated with Nusinersen: a\u00a0critical review and meta-analysis. Orphanet J Rare Dis 16(1):430","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"1462_CR26","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1002\/acn3.51562","volume":"9","author":"RS Finkel","year":"2022","unstructured":"Finkel\u00a0RS, Ryan\u00a0MM, Pascual\u00a0SI, Day\u00a0JW, Mercuri\u00a0E, De Vivo\u00a0DC, Foster\u00a0R, Montes\u00a0J, Gurgel-Giannetti\u00a0J, MacCannell\u00a0D et al (2022) Scientific rationale for a\u00a0higher dose of nusinersen. Ann Clin Transl Neurol 9(6):819\u2013829","journal-title":"Ann Clin Transl Neurol"},{"key":"1462_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15499","author":"E Mercuri","year":"2022","unstructured":"Mercuri\u00a0E, Baranello\u00a0G, Boespflug-Tanguy\u00a0O, De Waele\u00a0L, Goemans\u00a0N, Kirschner\u00a0J, Masson\u00a0R, Mazzone\u00a0ES, Pechmann\u00a0A, Pera\u00a0MC et al (2022) Risdiplam in types\u00a02 and\u00a03 spinal muscular atrophy: a\u00a0randomised, placebo-controlled, dose-finding trial followed by 24\u00a0months of treatment. Eur J Neurol. https:\/\/doi.org\/10.1111\/ene.15499","journal-title":"Eur J Neurol."},{"issue":"1","key":"1462_CR28","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s13023-022-02420-8","volume":"17","author":"A Hahn","year":"2022","unstructured":"Hahn\u00a0A, G\u00fcnther\u00a0R, Ludolph\u00a0A, Schwartz\u00a0O, Trollmann\u00a0R, Weydt\u00a0P, Weiler\u00a0M, Neuland\u00a0K, Schwaderer\u00a0MS, Hagenacker\u00a0T (2022) Short-term safety results from compassionate use of risdiplam in patients with spinal muscular atrophy in Germany. Orphanet J Rare Dis 17(1):276","journal-title":"Orphanet J Rare Dis"},{"issue":"17-18","key":"1462_CR29","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1089\/hum.2022.054","volume":"33","author":"B Stolte","year":"2022","unstructured":"Stolte\u00a0B, Schreiber-Katz\u00a0O, G\u00fcnther\u00a0R, Wurster\u00a0CD, Petri\u00a0S, Osmanovic\u00a0A, Freigang\u00a0M, Uzelac\u00a0Z, Leo\u00a0M, von Velsen\u00a0O et al (2022) Prevalence of anti-adeno-associated virus serotype 9 antibodies in adult patients with spinal muscular atrophy. Hum Gene Ther 33(17-18):968\u2013976","journal-title":"Hum Gene Ther"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-023-01462-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00115-023-01462-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-023-01462-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T22:58:49Z","timestamp":1702162729000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00115-023-01462-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,30]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["1462"],"URL":"https:\/\/doi.org\/10.1007\/s00115-023-01462-y","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,30]]},"assertion":[{"value":"6 February 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"H.\u00a0K\u00f6lbel gibt an: Vortr\u00e4ge in Industriesymposien (Pfizer, Roche, Novartis und Sanofi) und Advisory Board (Avexis\/Novartis). T.\u00a0Hagenacker gibt an: Advisory Board, Vortr\u00e4ge und Unterst\u00fctzung bei Forschungsaktivit\u00e4ten von Biogen, Roche und Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}